Related Experiment Video
Updated: Mar 6, 2026
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
Potential targeting of B7-H4 for the treatment of cancer
Joseph R Podojil1, Stephen D Miller1
1Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Abstract:
Observations noting the presence of white blood cell infiltrates within tumors date back more than a century, however the cellular and molecular mechanisms regulating tumor immunity continue to be elucidated. The recent successful use of monoclonal antibodies to block immune regulatory pathways to enhance tumor-specific immune responses for the treatment of cancer has encouraged the identification of additional immune regulatory receptor/ligand pathways. Over the past several years, a growing body of data has identified B7-H4 (VTCN1/B7x/B7S1) as a potential therapeutic target for the treatment of cancer. The potential clinical significance of B7-H4 is supported by the high levels of B7-H4 expression found in numerous tumor tissues and correlation of the level of expression on tumor cells with adverse clinical and pathologic features, including tumor aggressiveness. The biological activity of B7-H4 has been associated with decreased inflammatory CD4+ T-cell responses and a correlation between B7-H4-expressing tumor-associated macrophages and FoxP3+ regulatory T cells (Tregs) within the tumor microenvironment. Since B7-H4 is expressed on tumor cells and tumor-associated macrophages in various cancer types, therapeutic blockade of B7-H4 could favorably alter the tumor microenvironment allowing for antigen-specific clearance tumor cells. The present review highlights the therapeutic potential of targeting B7-H4.
Insights
B7-H4 is a protein found in many tumors that suppresses immune responses. Blocking B7-H4 may enhance anti-tumor immunity, offering a new cancer treatment strategy.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumor-infiltrating white blood cells indicate immune activity within tumors.
- Monoclonal antibodies targeting immune checkpoints have shown success in cancer therapy.
- B7-H4 (VTCN1) is an emerging immune regulatory molecule implicated in cancer progression.
Purpose of the Study:
- To review the therapeutic potential of targeting B7-H4 in cancer treatment.
- To highlight the role of B7-H4 in regulating the tumor microenvironment and immune responses.
Main Methods:
- Literature review of studies investigating B7-H4 expression and function in various cancers.
- Analysis of the association between B7-H4 expression and clinical/pathologic features.
- Examination of B7-H4's impact on immune cells, including CD4+ T cells, regulatory T cells (Tregs), and tumor-associated macrophages.
Main Results:
- High B7-H4 expression is observed in numerous tumor tissues and correlates with adverse clinical features and tumor aggressiveness.
- B7-H4 biological activity is linked to suppressed inflammatory CD4+ T-cell responses.
- B7-H4 expression on tumor cells and macrophages is associated with Tregs in the tumor microenvironment.
Conclusions:
- Therapeutic blockade of B7-H4 presents a promising strategy to enhance anti-tumor immunity.
- Targeting B7-H4 could modulate the tumor microenvironment, promoting antigen-specific tumor cell clearance.
- B7-H4 represents a significant potential therapeutic target for various cancer types.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...